Dublin, April 04, 2017 -- Research and Markets has announced the addition of the "Global Markets for Diabetes Therapeutics and Diagnostics" report to their offering.
The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Key Topics Covered:
1: Introduction
- Study Goals And Objectives
- Reasons For Doing The Study
- Scope Of Report
- Market Analyses And Forecasts
- Methodology
- Intended Audience
- Information Sources
2: Summary
- The Diabetes Market
- Leading Companies
3: Overview
- Diabetes Basics
- Current Treatment Of Diabetes
- The Diabetes Industry
4: Products And Suppliers
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Drugs
- Diagnosis And Monitoring
- Blood Glucose Monitoring Devices And Suppliers
- Other Testing Approaches
- Software Aids To Diabetes Monitoring
5: New Developments In Diabetes
- New Insulin Formulations And Combinations
- Improved Oral Antidiabetic Drugs
- New Developments In Glucose Testing
- Radical Approaches
6: The Global Diabetes Market
- Market Components
- Market Analysis By Product Category
- Trends
- Regional Segmentation
- National Markets
- National Markets In Detail
7: Company Profiles
- Leading Companies
- Other Companies
8: Appendix I About Diabetes
- Blood Sugar Regulation
- Insulin
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Obesity-Related Type 2 Diabetes In Children
- Mature-Onset Diabetes Of The Young (Mody)
- Other Diabetic States
9: Appendix
Companies Mentioned
- 77 Elektronika Kft.
- A. Menarini Diagnostics S.R.L.
- Abbott Laboratories
- Agamatrix Inc.
- Animas Corp.
- Ascensia
- Becton Dickinson
- Debiotech S.A.
- Eli Lilly And Co.
- Glaxo Smithkline
- Inlight Solutions Inc.
- Johnson & Johnson
- Lifescan Inc.
- Medtronic
- Merck & Co.
- Merck KGAA
- Nipro Corp.
- Novartis Pharma Ag
- Novo Nordisk A/S
- Owen Mumford Ltd.
- Palco Labs Inc.
- Roche
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
- Terumo Corp.
For more information about this report visit http://www.researchandmarkets.com/research/9sd6n2/global_markets
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diagnostics, Endocrine and Metabolic Disorders Drugs


Washington Post Publisher Will Lewis Steps Down After Layoffs
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



